JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

86.32 -0.94

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

85.91

Max

86.37

Schlüsselkennzahlen

By Trading Economics

Einkommen

-6.2M

-49M

Verkäufe

-9.1M

33M

Gewinnspanne

-151.352

Angestellte

283

EBITDA

-9.5M

-47M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+19.41% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.8B

5.8B

Vorheriger Eröffnungskurs

87.26

Vorheriger Schlusskurs

86.32

Nachrichtenstimmung

By Acuity

81%

19%

350 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Juli 2025, 17:53 UTC

Wichtige Markttreiber

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25. Juli 2025, 15:58 UTC

Ergebnisse
Wichtige Markttreiber

Aon Shares Rise After 2Q Earnings Beat

25. Juli 2025, 15:08 UTC

Wichtige Markttreiber

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25. Juli 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25. Juli 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25. Juli 2025, 20:40 UTC

Ergebnisse

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. Juli 2025, 20:10 UTC

Ergebnisse

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 19:56 UTC

Ergebnisse

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25. Juli 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25. Juli 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25. Juli 2025, 19:01 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Sale Could Fetch Around $1B, Sources Say -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH in Talks to Sell Marc Jacobs -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25. Juli 2025, 17:38 UTC

Wichtige Markttreiber

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25. Juli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25. Juli 2025, 17:13 UTC

Ergebnisse

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. Juli 2025, 16:46 UTC

Ergebnisse

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25. Juli 2025, 16:45 UTC

Ergebnisse

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25. Juli 2025, 16:27 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. Juli 2025, 16:02 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25. Juli 2025, 15:34 UTC

Ergebnisse

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25. Juli 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25. Juli 2025, 15:05 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25. Juli 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25. Juli 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25. Juli 2025, 14:36 UTC

Market Talk
Ergebnisse

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

19.41% Vorteil

12-Monats-Prognose

Durchschnitt 104.21 USD  19.41%

Hoch 130 USD

Tief 80 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

14

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

350 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.